JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266585

Human PTPRF (LAR) knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PTPRF KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 4 and 5 bp deletion in exon 4. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

FLJ43335, FLJ45062, FLJ45567, LAR protein, LARFN5C, LARS, LCA homolog, Leukocyte antigen related, Leukocyte antigen related (LAR) PTP receptor, Leukocyte antigen related PTP receptor, Leukocyte antigen related tyrosine phosphatase, Leukocyte common antigen related, PTPRF protein, PTPRF_HUMAN, Protein Tyrosine Phosphatase Receptor Type F, Protein tyrosine phosphatase receptor type F polypeptide, Receptor linked protein tyrosine phosphatase LAR, Receptor type tyrosine protein phosphatase F precursor, Receptor-type tyrosine-protein phosphatase F

2 Images
Sanger Sequencing - Human PTPRF (LAR) knockout HEK-293T cell line (AB266585)
  • Sanger seq

Unknown

Sanger Sequencing - Human PTPRF (LAR) knockout HEK-293T cell line (AB266585)

Allele-2 : 1 bp insertion in exon 4.

Sanger Sequencing - Human PTPRF (LAR) knockout HEK-293T cell line (AB266585)
  • Sanger seq

Unknown

Sanger Sequencing - Human PTPRF (LAR) knockout HEK-293T cell line (AB266585)

Allele-1 : 5 bp deletion in exon 4

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 4 and 5 bp deletion in exon 4

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266585-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266585-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266585 Human PTPRF (LAR) knockout HEK-293T cell line", "number":"AB266585-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266585-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266585-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266585 Human PTPRF (LAR) knockout HEK-293T cell line", "number":"AB266585-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266585-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266585 Human PTPRF (LAR) knockout HEK-293T cell line", "number":"AB266585-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266585-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266585 Human PTPRF (LAR) knockout HEK-293T cell line", "number":"AB266585-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PTPRF
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein LAR also known as Leukocyte Common Antigen-Related phosphatase is a receptor-like protein tyrosine phosphatase. It weighs approximately 220 kDa. LAR is expressed in various tissues including the nervous system and digestive tract. It comprises an extracellular domain a single transmembrane domain and two intracellular phosphatase domains which play a significant role in its interaction with other proteins.
Biological function summary

This receptor-like phosphatase supports important cell signaling functions. LAR is involved in neural development processes and is part of the synaptic adhesion complex. By interacting with proteins in the plasma membrane it helps modify and maintain neural connectivity necessary for proper nerve function. Its activity influences actin cytoskeleton dynamics and cell-cell adhesion.

Pathways

LAR plays a role in the axon guidance and insulin signaling pathways. In axon guidance it interacts with proteins such as netrin and nneural cell adhesion molecule (NCAM) to facilitate correct neural wiring. In the insulin signaling pathway LAR can dephosphorylate key proteins like insulin receptor affecting glucose metabolism and overall energy homeostasis.

Research shows that LAR may be linked to diabetes and potential neurological disorders. In diabetes its interaction with the insulin receptor suggests a role in insulin resistance which is a major contributing factor in the disease. In neurological disorders LAR's dysregulation can affect neural development and function possibly linking it to diseases like schizophrenia where cell signaling and connectivity changes are observed.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com